ClinicalTrials.gg
CompletedNCT01225822Updated May 19, 2014Results posted

BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery

A Phase 2 interventional study of Enoxaparin and BIBR 1048 in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 59 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,973
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.

Enrollment
3rd of 17
1,973 · median 148
Started
2002
with 1 other
Phase 2
7 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 3rd largest by enrollment, is one of 2 that started in 2002, is one of 7 in phase 2, and was the 7th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dabigatran

Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing dabigatran in Venous Thromboembolism, or all of them as a file.
02

Study summary

The primary objective of this study is to establish the dose-response relationship with regard to efficacy and safety of BIBR 1048 (50 mg bis in die(b.i.d), 150 mg b.i.d, 225 mg b.i.d. and 300 mg quaque die(q.d) ) in preventing venous thromboembolism(VTE) in patients undergoing primary elective total hip and knee replacement.

03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients scheduled to undergo a primary elective total hip or knee replacement.
  2. Male of female being 18 years or older.
  3. Patients weighing at least 40 kg.
  4. Written for study participation.

Exclusion criteria

Exclusion criteria

  1. Bleeding diathesis, constitutional or acquired coagulation disorders.
  2. Major surgery or trauma(e.g., hip fracture) within the last 3 months.
  3. Cardiovascular disease
  4. Any history of haemorrhagic stroke, intracranial or intraocular bleeding or cerebral ischaemic attacks lasting more than 24 hours and / or with cardiovascular pathological findings.
  5. Deep vein thrombosis(DVT), gastrointestinal or pulmonary bleeding, gastric or duodenal ulcer within the last year.
  6. History of or acute intracranial disease
  7. Liver disease
  8. Renal disease
  9. Use of long-term anticoagulants or antiplatelet drugs within 7 days prior to hip/knee replacement operation.
  10. Pre-menopausal women who are not surgically steriles, are nursing and are of and are not practising acceptable methods of
  11. Known allergy to contrast media
  12. Thrombocytopenia
  13. Allergy against heparin.
  14. Active malignant disease or current cytostatic treatment.
  15. Treatment with an drug in the past month.
  16. Leg amputee
  17. Known alcohol or drug abuse
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,973 participants (actual)

Study arms

  • Experimental
    BIBR 1048 50 mg bis in die(b.i.d)

    BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period

    Drug: BIBR 1048

  • Experimental
    BIBR 1048 150 mg b.i.d

    BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period

    Drug: BIBR 1048

  • Experimental
    BIBR 1048 225 mg b.i.d

    BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period

    Drug: BIBR 1048

  • Experimental
    BIBR 1048 300 mg quaque die(q.d)

    BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period

    Drug: BIBR 1048

  • Active comparator
    Enoxaparin 40 mg subcutaneous(s.c)

    placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period

    Drug: Enoxaparin

Interventions

  • Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period

  • 50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period

  • 150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period

  • 225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period

  • 300 mg q.d BIBR 1048 capsule for 5-10 treatment period

06

What researchers measure

Primary outcomes

  1. Number of Participants With Venous Thromboembolic (VTE) Events

    Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing

    Time frame: Treatment period (up to day 8+/-2 days visit)

  2. Number of Participants With Major Bleeding Events (MBE)

    Time frame: From approximately 14 days prior to surgery to 4-6 weeks post surgery

Secondary outcomes

  1. Number of Participants With VTE Events and All Cause Mortality

    Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.

    Time frame: Treatment period (up to day 8+/-2 days visit)

  2. Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality

    Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality

    Time frame: Treatment period (up to day 10)

  3. Number of Participants With Proximal DVT

    Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period

    Time frame: Treatment period (up to day 8+/-2 days visit)

  4. Volume of Blood Loss

    Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.

    Time frame: Day 1 (Day of surgery)

  5. Rate of Transfusions Due to Bleedings

    Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.

    Time frame: Day 1 (Day of surgery)

  6. Number of Participants With Clinically Significant, Minor or Any Bleeding Events

    Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as * Spontaneous skin haematoma larger than \>25 cm² * Wound haematoma \>100 cm² * Spontaneous nose bleed \>5 minutes * Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention * Spontaneous rectal bleeding (more than spot on toilet paper) * Gingival bleeding \>5 minutes * Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.

    Time frame: Treatment period (up to day 8+/-2 days visit)

  7. Laboratory Analyses

    Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range. Normal ranges are defined as: Haematocrit \[%\]: (0.35-0.45) for women and (0.39-0.51) for men Haemoglobin \[g/dL\]: (11.6-15.4) for women and (13.2-17.3) for men White Blood Cell count \[10\^9/L\]: (4-10.3) for women and (3.9-10.3) for men Platelets \[10\^9/L\]: (145-420) for women and men Sodium \[mmol/L\]: (135-146) for women and men Potassium \[mmol/L\]: (3.5-5) for women and men Aspartate aminotransferase (AST) \[U/L\]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) \[U/L\]: (8-43) for women and (8-45) for men Alkaline Phosphatase \[U/L\]: (36-118) for women and (35-123) for men Creatinine \[mg/dL\]: (0.57-1.06)for women and (0.72-1.3) for men Bilirubin, total \[mg/dL\]: (0.22-1.28) for women and men Uric acid \[mg/dL\]: (2.4-6.47) for women and men

    Time frame: Screening to end of treatment

  8. Plasma Concentration (Cmax) of Dabigatran

    Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state. Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state. Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state

    Time frame: Day 1 to end of treatment

  9. Area Under the Plasma Concentration-time Curve During a Dosing Interval

    Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.

    Time frame: up to day 8+/-2 days visit

07

Results

Posted Dec 16, 2010

Participant flow

There were 1973 patients enrolled/randomised in this trial but only 1949 started treatment

Participant flow — Overall Study
MilestoneBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Started389390393385392
Completed351334355333361
Not completed3856385231
Withdrew: Adverse event1331182314
Withdrew: Protocol violation68674
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by subject677116
Withdrew: Other13107107

Outcome measures

PrimaryNumber of Participants With Venous Thromboembolic (VTE) Events

Deep vein thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or PE confirmed by objective testing

Time frame:
Treatment period (up to day 8+/-2 days visit)
Reported as:
Number · participants
Number of Participants With Venous Thromboembolic (VTE) Events
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Number of Participants With Venous Thromboembolic (VTE) Events8649394772
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = <0.0001 (Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid) · Odds ratio (or): 0.375 · 95% CI 0.244 to 0.577
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.0015 (Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid) · Odds ratio (or): 0.518 · 95% CI 0.344 to 0.778
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.7856 · Odds ratio (or): 0.94 · 95% CI 0.599 to 1.473
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0007 · Odds ratio (or): 0.469 · 95% CI 0.302 to 0.727
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0401 · Odds ratio (or): 0.647 · 95% CI 0.427 to 0.98
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.2446 · Odds ratio (or): 1.249 · 95% CI 0.859 to 1.817
SecondaryNumber of Participants With VTE Events and All Cause Mortality

Deep venous thrombosis (DVT) (proximal and distal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic DVT confirmed by venography during the treatment period or Pulmonary Embolism (PE) confirmed by objective testing and all deaths.

Time frame:
Treatment period (up to day 8+/-2 days visit)
Reported as:
Number · participants
Number of Participants With VTE Events and All Cause Mortality
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Number of Participants With VTE Events and All Cause Mortality8649394772
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = <0.0001 (Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid) · Odds ratio (or): 0.375 · 95% CI 0.244 to 0.577
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.0015 (Dose relationship tested using a hierarchical testing procedure to preserve type I error rate at 5%. 225 mg bid was compared to 50 mg bid. If a difference significant at 5% level was found, then 150 mg bid was compared to 50 mg bid) · Odds ratio (or): 0.518 · 95% CI 0.344 to 0.778
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.7856 · Odds ratio (or): 0.94 · 95% CI 0.599 to 1.473
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0007 · Odds ratio (or): 0.469 · 95% CI 0.302 to 0.727
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0401 · Odds ratio (or): 0.647 · 95% CI 0.427 to 0.98
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.2446 · Odds ratio (or): 1.249 · 95% CI 0.859 to 1.817
SecondaryNumber of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality

Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period or PE confirmed by objective testing plus VTE related mortality

Time frame:
Treatment period (up to day 10)
Reported as:
Number · participants
Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Number of Participants With Proximal DVT, PE (Pulmonary Embolism) and VTE Related Mortality15115617
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = 0.0373 · Odds ratio (or): 0.334 · 95% CI 0.199 to 0.938
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.6659 · Odds ratio (or): 0.837 · 95% CI 0.374 to 1.875
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.1882 · Odds ratio (or): 0.505 · 95% CI 0.183 to 1.397
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.5566 · Odds ratio (or): 0.805 · 95% CI 0.39 to 1.66
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.3253 · Odds ratio (or): 0.674 · 95% CI 0.307 to 1.48
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0114 · Odds ratio (or): 0.269 · 95% CI 0.097 to 0.744
SecondaryNumber of Participants With Proximal DVT

Deep venous thrombosis (DVT) (proximal) as detected by routine bilateral venography on day 8 +/- 2, plus symptomatic proximal DVT confirmed by venography during the treatment period

Time frame:
Treatment period (up to day 8+/-2 days visit)
Reported as:
Number · participants
Number of Participants With Proximal DVT
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Number of Participants With Proximal DVT1595617
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = 0.036 · Odds ratio (or): 0.332 · 95% CI 0.118 to 0.931
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.3884 · Odds ratio (or): 0.687 · 95% CI 0.293 to 1.611
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.3674 · Odds ratio (or): 0.616 · 95% CI 0.215 to 1.766
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.5663 · Odds ratio (or): 0.809 · 95% CI 0.393 to 1.668
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.1678 · Odds ratio (or): 0.556 · 95% CI 0.242 to 1.28
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0113 · Odds ratio (or): 0.269 · 95% CI 0.097 to 0.743
PrimaryNumber of Participants With Major Bleeding Events (MBE)
Time frame:
From approximately 14 days prior to surgery to 4-6 weeks post surgery
Reported as:
Number · participants
Number of Participants With Major Bleeding Events (MBE)
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Number of Participants With Major Bleeding Events (MBE)11615188
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = 0.0077 · Odds ratio (or): 15.818 · 95% CI 2.077 to 120.474
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.0062 · Odds ratio (or): 16.907 · 95% CI 2.229 to 128.238
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.7192 · Odds ratio (or): 1.136 · 95% CI 0.567 to 2.276
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0472 · Odds ratio (or): 0.121 · 95% CI 0.015 to 0.974
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.1043 · Odds ratio (or): 2.049 · 95% CI 0.862 to 4.868
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.1448 · Odds ratio (or): 1.917 · 95% CI 0.799 to 4.597
SecondaryVolume of Blood Loss

Volume of blood loss was to be analysed using an analysis of variance (ANOVA), which included treatment and centre.

Time frame:
Day 1 (Day of surgery)
Reported as:
Mean · ml
Volume of Blood Loss
mlBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Volume of Blood Loss523.3 ± 845.81538.4 ± 1474.5631.4 ± 720.9910.3 ± 918.3945.5 ± 651.3
SecondaryRate of Transfusions Due to Bleedings

Percentage of patients requiring transfusions due to bleeding .Rate of need of transfusion were to be analysed using a logistic regression with treatment and centre.

Time frame:
Day 1 (Day of surgery)
Reported as:
Number · Percentage of patients
Rate of Transfusions Due to Bleedings
Percentage of patientsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Rate of Transfusions Due to Bleedings0.265.384.074.943.57
Statistical analysis
  • BIBR 1048 50 mg Bid vs BIBR 1048 225 mg Bid · Regression, Logistic · p = 0.0063 · Odds ratio (or): 16.871 · 95% CI 2.221 to 128.142
  • BIBR 1048 50 mg Bid vs BIBR 1048 150 mg Bid · Regression, Logistic · p = 0.0025 · Odds ratio (or): 22.338 · 95% CI 2.983 to 167.268
  • BIBR 1048 150 mg Bid vs BIBR 1048 300 mg qd · Regression, Logistic · p = 0.7973 · Odds ratio (or): 0.919 · 95% CI 0.483 to 1.750
  • BIBR 1048 50 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.0097 · Odds ratio (or): 0.068 · 95% CI 0.009 to 0.522
  • BIBR 1048 150 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.2375 · Odds ratio (or): 1.522 · 95% CI 0.758 to 3.058
  • BIBR 1048 225 mg Bid vs Enoxaparin 40 mg qd · Regression, Logistic · p = 0.7104 · Odds ratio (or): 1.150 · 95% CI 0.550 to 2.403
SecondaryNumber of Participants With Clinically Significant, Minor or Any Bleeding Events

Number of participants with Clinically Significant, minor or any bleeding events. Clinically significant bleeding events are defined as * Spontaneous skin haematoma larger than \>25 cm² * Wound haematoma \>100 cm² * Spontaneous nose bleed \>5 minutes * Macroscopic haematurea, either spontaneous or lasting more than 24 hours if associated with an intervention * Spontaneous rectal bleeding (more than spot on toilet paper) * Gingival bleeding \>5 minutes * Any other bleeding event considered as clinically significant by the investigator All other bleeding events that did not fulfil the criteria of MBE or clinically significant bleeding event were classified as minor bleeding events.

Time frame:
Treatment period (up to day 8+/-2 days visit)
Reported as:
Number · participants
Number of Participants With Clinically Significant, Minor or Any Bleeding Events
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Clinically significant bleeding events916201910
Minor bleeding events1831383725
Any bleeding events2661656243
SecondaryLaboratory Analyses

Number of patients with possible clinically significant abnormalities, i.e. with values out of normal range. Normal ranges are defined as: Haematocrit \[%\]: (0.35-0.45) for women and (0.39-0.51) for men Haemoglobin \[g/dL\]: (11.6-15.4) for women and (13.2-17.3) for men White Blood Cell count \[10\^9/L\]: (4-10.3) for women and (3.9-10.3) for men Platelets \[10\^9/L\]: (145-420) for women and men Sodium \[mmol/L\]: (135-146) for women and men Potassium \[mmol/L\]: (3.5-5) for women and men Aspartate aminotransferase (AST) \[U/L\]: (11-37) for women and (11-39) for men Alanine aminotransferase (ALT) \[U/L\]: (8-43) for women and (8-45) for men Alkaline Phosphatase \[U/L\]: (36-118) for women and (35-123) for men Creatinine \[mg/dL\]: (0.57-1.06)for women and (0.72-1.3) for men Bilirubin, total \[mg/dL\]: (0.22-1.28) for women and men Uric acid \[mg/dL\]: (2.4-6.47) for women and men

Time frame:
Screening to end of treatment
Reported as:
Number · participants
Laboratory Analyses
participantsBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Haematocrit decrease (N=325,324,339,320,340)1615141422
Haemoglobin decrease (N=325,324,339,320,340)122129148129142
White blood cell ct. decr.(N=325,324,339,320,340)00210
Platelets decrease (N=325,324,339,320,340)00001
Platelets increase (N=325,324,339,320,340)01100
Sodium decrease (N=340,334,344,327,352)02010
Potassium decrease (N=340,334,344,326,352)00102
Potassium increase (N=340,334,344,326,352)02121
AST increase (N=340,334,344,327,352)10239
ALT increase (N=340,334,344,327,352)653820
Alkaline phosphatase incr. (N=340,334,344,327,352)12003
Creatinine increase (N=340,334,344,327,352)02011
Bilirubin, total increase (N=340,334,344,327,352)00010
Uric Acid increase (N=340,334,344,327,352)34423
SecondaryPlasma Concentration (Cmax) of Dabigatran

Maximum plasma concentration of Dabigatran (at steady-state) and Pre-dose plasma concentrations at steady state. Cmax represents the maximum concentration of Dabigatran in plasma. Cmax,ss represents the maximum concentration of Dabigatran in plasma at steady state. Cpre,ss represents pre-dose concentration of Dabigatran in plasma at steady state

Time frame:
Day 1 to end of treatment
Reported as:
Geometric mean · ng/mL
Plasma Concentration (Cmax) of Dabigatran
ng/mLBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Cmax (N=88, 83, 84, 96, 0)24.5 ± 11560.5 ± 97.379.9 ± 94.7132 ± 81.6—
Cmax at steady-state (N=87, 74, 79, 85, 0)48.0 ± 64.6165 ± 63.6257 ± 62.7271 ± 75.2—
Cpre at steady-state19.6 ± 70.770.3 ± 87.3113 ± 80.938.0 ± 85.9—
SecondaryArea Under the Plasma Concentration-time Curve During a Dosing Interval

Area under the plasma concentration-time curve during a dosing interval (at steady-state). The AUC0-12h (for b.i.d. treatment regimens) and AUC0-24h (300 mg q.d.) after the first dose on day of surgery calculated by extrapolation using the elimination rate constant, reported only if the extrapolated fraction of AUC was less than 30 % of the total AUC.

Time frame:
up to day 8+/-2 days visit
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve During a Dosing Interval
ng*h/mLBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
AUC during a dosing interval (N=13,12,21,72,0)229 ± 88.1636 ± 56.2605 ± 91.61610 ± 82.5—
AUC during a dosing interval at steady-state350 ± 66.81250 ± 64.81910 ± 64.92450 ± 76.1—

Adverse events

Collected over 14 days +/- 2 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIBR 1048 50 mg Bid—25/389 (6.4%)242/389 (62.2%)
BIBR 1048 150 mg Bid—29/390 (7.4%)267/390 (68.5%)
BIBR 1048 225 mg Bid—21/393 (5.3%)256/393 (65.1%)
BIBR 1048 300 mg qd—33/385 (8.6%)267/385 (69.4%)
Enoxaparin 40 mg qd—31/392 (7.9%)258/392 (65.8%)
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
Venous thrombosis deep limbVascular disorders5/3891/3901/3931/3852/392
Wound infection NECInfections and infestations1/3891/3903/3933/3853/392
Joint dislocation NECInjury, poisoning and procedural complications0/3893/3900/3933/3851/392
Post procedural haemorrhageInjury, poisoning and procedural complications1/3890/3902/3933/3851/392
Pulmonary embolismVascular disorders1/3893/3900/3930/3850/392
Deep venous thrombosis NOSVascular disorders1/3890/3900/3931/3853/392
Rectal haemorrhageGastrointestinal disorders0/3891/3901/3932/3851/392
PyrexiaGeneral disorders0/3890/3900/3932/3850/392
Post-operative wound infectionInfections and infestations1/3890/3900/3932/3850/392
Dislocation of joint prosthesisInjury, poisoning and procedural complications1/3890/3901/3932/3851/392
Most frequent other events
Showing 10 of 14
Most frequent other events
EventBIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qd
NauseaGastrointestinal disorders84/389105/39092/393105/385111/392
Vomiting NOSGastrointestinal disorders76/38977/39075/39376/38566/392
InsomniaPsychiatric disorders59/38945/39052/39359/38551/392
ConstipationGastrointestinal disorders33/38938/39034/39346/38534/392
PyrexiaGeneral disorders33/38930/39036/39335/38532/392
Venous thrombosis deep limbVascular disorders33/38912/39013/39312/38516/392
Anaemia NOSBlood and lymphatic system disorders23/38926/39027/39322/38518/392
Hypotension NOSVascular disorders19/38925/39021/39321/38520/392
Post procedural drainageInjury, poisoning and procedural complications12/38916/39023/39318/3858/392
Wound secretionInjury, poisoning and procedural complications15/38921/39016/39317/3856/392

Baseline characteristics

Age, Customized
Age, Customized(years)BIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qdTotal
Mean66.07 ± 10.2365.86 ± 10.7765.87 ± 10.6366.47 ± 10.3765.03 ± 11.0365.86 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)BIBR 1048 50 mg BidBIBR 1048 150 mg BidBIBR 1048 225 mg BidBIBR 1048 300 mg qdEnoxaparin 40 mg qdTotal
Female2232522292462411191
Male166138164139151758
08

Study locations

59 sites
  • 1160.19.43004 Krankenhaus der Barmherzigen Schwestern Linz
    Linz, Austria
  • 1160.19.43002 Orthopädisches Spital Speising
    Wien, Austria
  • 1160.19.43001 A.ö. Krankenhaus d. Statutarstadt Wiener Neustadt
    Wr. Neustadt, Austria
  • 1160.19.32002 V.U.B. Jette
    Brussel, Belgium
  • 1160.19.32004 UZ Gent
    Gent, Belgium
  • 1160.19.32005 Virga Jesseziekenhuis
    Gent, Belgium
  • 1160.19.32006 Boehringer Ingelheim Investigational Site
    Huy, Belgium
  • 1160.19.32007 C.H.U. de Tivoli
    La Louvière, Belgium
  • 1160.19.42004 University Hospital Brno
    Brno-Bohunice, Czech Republic
  • 1160.19.42001 Hospital Kladno
    Kladno, Czech Republic
  • 1160.19.42006 Hospital Mlada Boleslav
    Mlada Boleslav, Czech Republic
  • 1160.19.42003 University Hospital Ostrava
    Ostrava, Czech Republic
  • 1160.19.42005 University Hospital Plzen
    Plzen, Czech Republic
  • 1160.19.42009 University Hospital Na Bulovce
    Prague 8, Czech Republic
  • 1160.19.45042 Orthopedic Surgical Clinic
    Frederiksberg, Denmark
  • 1160.19.45045 Gentofte Hospital
    Hellerup, Denmark
  • 1160.19.45043 Herlev Hospital
    Herlev, Denmark
  • 1160.19.45041 Hørsholm Sygehus
    Hørsholm, Denmark
  • 1160.19.45044 Orthopedic Surgical Dept.
    Silkeborg, Denmark
  • 1160.19.35802 Keski-Suomen keskussairaala
    Jyväskylä, Finland
  • 1160.19.35801 Oulun yliopistollinen sairaala, Leikkaus- ja tehohoidon yks.
    Oulu, Finland
  • 1160.19.33004 Div
    Illkirch cedex, France
  • 1160.19.33007 Clinique du Mail
    La Rochelle, France
  • 1160.19.33009 Hôpital Edouard Herriot
    Lyon cedex 03, France
  • 1160.19.33006 Clinique Mutualiste
    Saint-Etienne cedex 2, France
  • 1160.19.33008 Clinique de l'Atlantique
    St Herblain cedex, France
  • 1160.19.36003 Sándor Péterfy Hospital
    Budapest, Hungary
  • 1160.19.36001 Kálmán Pándy County Hospital
    Gyula, Hungary
  • 1160.19.36004 Bács-Kiskun County Hospital
    Kecskemét, Hungary
  • 1160.19.36002 Albert Szent-Györgyi Medical and Pharmacological Center
    Szeged, Hungary
  • 1160.19.36005 Szent György Hospital
    Székesfehérvár, Hungary
  • 1160.19.39003 U. O. Ortopedia e Traumatologia
    Bergamo, Italy
  • 1160.19.39005 Modulo Coordinazione Dipartimentale di Ricerca e Anestesia
    Bologna, Italy
  • 1160.19.39002 Fondazione Centro S. Raffaele
    Milano, Italy
  • 1160.19.39001 IRCCS Policlinico San Matteo
    Pavia, Italy
  • 1160.19.39004 Ospedale di Circolo di Varese
    Varese, Italy
  • 1160.19.31001 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1160.19.31003 Boehringer Ingelheim Investigational Site
    Hilversum, Netherlands
  • 1160.19.31005 Hengstdal 3
    Nijmegen, Netherlands
  • 1160.19.31006 Boehringer Ingelheim Investigational Site
    Sittard, Netherlands
  • 1160.19.31004 Boehringer Ingelheim Investigational Site
    Zwolle, Netherlands
  • 1160.19.47001 Nordlandssykehuset HF, Bodø
    Bodø, Norway
  • 1160.19.47004 Martina Hansens Hospital
    Bærum Postterminal, Norway
  • 1160.19.47008 Martina Hansens Hospital
    Bærum Postterminal, Norway
  • 1160.19.47007 Sykehuset Innlandet HF, Avd. Elverum
    Elverum, Norway
  • 1160.19.47005 Haugesund sjukehus HF
    Haugesund, Norway
  • 1160.19.47002 Sykehuset Telemark HF, Avd. Skien
    Skien, Norway
  • 1160.19.47003 Helse Sunnmøre HF, Ålesund sykehus
    Ålesund, Norway
  • 1160.19.27001 Dept. of Haematology
    Johannesburg, South Africa
  • 1160.19.27002 Suite 203
    Johannesburg, South Africa
  • 1160.19.46002 Kirurgavdelningen
    Falköping, Sweden
  • 1160.19.46001
    Göteborg, Sweden
  • 1160.19.46004 Ortopediska kliniken, Länssjukhuset, Halmstad
    Halmstad, Sweden
  • 1160.19.46003 Ortopediska kliniken, Länssjukhuset i Kalmar
    Kalmar, Sweden
  • 1160.19.46007 Kungälvs sjukhus
    Kungälvs, Sweden
  • 1160.19.46005 Kirurg Ortopediska kliniken, Sjukhuset i Lidköping
    Lidköping, Sweden
  • 1160.19.46008 Ortopediska Institutionen
    Linköping, Sweden
  • 1160.19.46009 Sahlgrenska Universitetssjukhuset, Mölndal
    Mölndal, Sweden
  • 1160.19.46006 Boehringer Ingelheim Investigational Site
    Varberg, Sweden
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a primary completion of Aug 2003. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 7 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2010
First posted
Oct 21, 2010
Start
Nov 2002
Primary completionActual
Aug 2003
Results first posted
Dec 16, 2010
Last update
May 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01225822
First posted
Oct 21, 2010
Start date
Nov 2002
Primary completion
Aug 2003
Results posted
Dec 16, 2010
Last update
May 19, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dabigatran

Start the discussion